COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00061867
Recruitment Status : Completed
First Posted : June 6, 2003
Last Update Posted : May 30, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die. Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. Combining liposomal doxorubicin with microwave thermotherapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given together with microwave thermotherapy in treating patients with prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: pegylated liposomal doxorubicin hydrochloride Procedure: hyperthermia treatment Phase 1

Detailed Description:


  • Determine the maximum tolerated dose of doxorubicin HCl liposome released through thermal microwave therapy in patients with adenocarcinoma of the prostate.
  • Determine the pharmacokinetics and biodistribution profile of this drug in these patients.
  • Determine the safety profile and dose-limiting toxicity of this drug in these patients.
  • Determine the clinical response in patients treated with this regimen.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive doxorubicin HCl liposome IV over 30 minutes. Patients then undergo a 60-minute course of prostate thermotherapy. Treatment may repeat every 28-42 days for up to 6 courses, at the discretion of the physician.

Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 8, 15, 30, and 90 days.

PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer
Study Start Date : March 2003
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate
  • Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate cancer by bone scan, CT scan, prostascint scan, or MRI



  • 40 and over

Performance status

  • Karnofsky 80-100%

Life expectancy

  • Not specified


  • WBC greater than 4,000/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 10.0 g/dL


  • Bilirubin normal
  • AST normal
  • Alkaline phosphatase normal
  • No acute or chronic liver disease


  • Creatinine less than 1.5 times upper limit of normal


  • Ejection fraction at least 50% by MUGA
  • EKG normal
  • No myocardial infarction or cerebral vascular accident within the past 6 months
  • No life threatening cardiac arrhythmias
  • No congestive heart failure
  • No cardiac pacemaker
  • No peripheral arterial disease with intermittent claudication or Leriches syndrome (i.e., claudication of the buttocks or perineum)


  • Fertile patients must use effective barrier contraception during and for 3 months after study participation
  • No sperm donation during and for 3 months after study participation
  • Not febrile
  • No interest in future fertility or fathering children
  • No significantly decreased pain response
  • No severe urethral stricture
  • No protruding median lobe resulting in a "ball-valve" type of obstruction at the bladder neck
  • No major psychiatric illness that would prevent informed consent
  • No major psychiatric illness that required inpatient treatment within the past 3 months
  • No psychological, family, sociological, or geographic condition that would preclude study compliance
  • No allergy to eggs or egg products
  • No urinary or prostatic infection
  • No full urinary retention
  • No penile or urinary sphincter implant
  • No metallic implants in the pelvic or femoral area
  • No other serious medical illness that would preclude study participation


Biologic therapy

  • No concurrent live vaccines


  • No prior anthracycline
  • No concurrent streptozocin

Endocrine therapy

  • No concurrent hormonal therapy (except luteinizing hormone-releasing hormone analog)
  • No concurrent glucocorticoids administered at more than physiologic replacement doses (other than as an antiemetic)


  • Not specified


  • More than 3 months since prior major surgery


  • No prior therapy that resulted in permanent reduction of pain response (e.g., prior surgery, regional or local anesthetic)
  • No concurrent PC-SPES
  • No concurrent cyclosporine, phenobarbital, or phenytoin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00061867

Layout table for location information
United States, Louisiana
Regional Urology, L.L.C.
Shreveport, Louisiana, United States, 71106
United States, South Carolina
Grand Strand Urology LLP
Myrtle Beach, South Carolina, United States, 29572
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Catherine Van Doren, RN Celsion
Layout table for additonal information Identifier: NCT00061867    
Other Study ID Numbers: CELSION-10302101
CDR0000301761 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 6, 2003    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: July 2005
Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the prostate
stage III prostate cancer
stage IV prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action